Choose the nasal spray for seconds-long needle-free bremelanotide or the mini troche for one compact oral-dissolve step. Both formats are refrigerated and designed around as-needed intimacy, bringing a centrally acting desire medication into two private at-home routines.
Current Rebody pricing: PT-141 nasal spray is $99.50 for the first month, then $199 per 5 mL bottle. PT-141 troches are $54.50 for the first month, then $109 per 8-count package for 1 mg; $59.50 for the first month, then $119 for 2 mg.
The short answer
Needle aversion is a real treatment constraint, especially for a product used around intimacy. Rebody's routes remove subcutaneous administration while preserving two distinct choices: a metered bottle used in seconds or a troche dissolved beneath the tongue or in the cheek.
The active, bremelanotide, improved desire and reduced distress in phase 3 trials of premenopausal women with acquired, generalized HSDD. Those trials tested injection; Rebody's nasal spray and troche keep their own route-specific dose and timing.
Needle-free formats at a glance
| Format | Strengths | Package | Storage | Best for |
|---|---|---|---|---|
| Nasal spray | 5 and 10 mg/mL | 5 mL bottle | Refrigerated | Fast physical administration |
| Mini troche | 1 and 2 mg | 10 count | Refrigerated | Avoiding nasal use and pump technique |
The label supplies dose, timing, maximum frequency, expected uses, and refill timing. The 10 mg/mL nasal spray is $99.50 first month, then $199 per 5 mL bottle; troches are $54.50 first month, then $109 per 8-count package for 1 mg; $59.50 first month, then $119 for 2 mg.
Why nasal wins the practical choice
A nasal actuation takes seconds and avoids waiting for a solid dosage form to dissolve. The bottle is compact and can be used without injection supplies.
That advantage depends on a functional pump and comfortable nasal tissue. Congestion, nosebleed, recent nasal procedure, irritation, leakage, or strong throat runoff can change delivery and experience.
Final instructions must define priming, metered output, sprays per use, nostril sequence, bottle cleaning, and what to do when the mist looks irregular. Do not compensate for uncertainty with extra sprays.
Why troche is the best exception
Troches avoid the nose and the pump. The mini unit is placed beneath the tongue or between gum and cheek as directed on the label.
That route adds dissolve time, taste, saliva, speaking, food and drink spacing, mouth irritation, and accidental swallowing. No direct outcome trial establishes either Rebody strength.
Choose 1 mg first when both are offered; 2 mg is a higher unit strength, not proof of a larger or more reliable desire response.
Needle-free is not Vyleesi without the needle
Vyleesi is a specific 1.75 mg subcutaneous bremelanotide injection. Its FDA label, pivotal trials, timing, dose, and maximum frequency belong to that finished product.
Changing to intranasal or oral-mucosal delivery changes absorption and exposure. A spray or troche should not be called generic Vyleesi or clinically equivalent.
The useful connection is the active and mechanism. The necessary separation is route, formula, dose, onset, and outcome evidence.
What the women's trials measured
The RECONNECT trials randomized 1,267 premenopausal women with acquired, generalized HSDD to 1.75 mg subcutaneous bremelanotide or placebo for 24 weeks.
Desire improved and distress related to low desire decreased versus placebo. A satisfying-sexual-event co-primary outcome did not improve significantly.
That finding should shape expectations: the treatment evidence concerns desire and distress, not guaranteed intercourse, orgasm, lubrication, or relationship closeness.
What the nasal women's study measured
A double-blind crossover experiment studied one 20 mg intranasal dose in 18 premenopausal women with female sexual arousal disorder. Researchers measured physiological and subjective arousal outcomes.
The study makes intranasal bremelanotide a researched route, but it does not establish Rebody's 10 mg/mL pump, prescribed actuation count, or HSDD outcome.
Do not translate the 20 mg study dose into retail sprays. Use the metered dose written on the prescription label.
Low desire must be the central symptom
Pain, dryness, medication side effects, depression, anxiety, sleep loss, postpartum change, menopause, chronic illness, relationship dynamics, and trauma can all change intimacy.
Bremelanotide is most coherent when desire itself has declined across situations and the change causes personal distress. It is not a lubricant or treatment for painful sex.
A needle-free format makes administration easier. It does not make a mismatched treatment appropriate for a different symptom.
Timing without injection assumptions
The approved injection is used at least 45 minutes before anticipated activity. Do not copy that lead time to spray or troche.
Nasal administration is physically quicker than troche dissolution, but clinical onset is not the same as administration time. Use the route-specific timing on the prescription label.
Do not redose because an internet timer expired. Final instructions must state lead time, assessment window, and maximum use.
Nausea and other side effects
Nausea was the most common Vyleesi adverse reaction. The label also addresses flushing, headache, vomiting, transient blood-pressure increases, reduced heart rate, focal hyperpigmentation, pregnancy, delayed gastric emptying, and oral naltrexone exposure.
Nasal route adds congestion, irritation, taste, runoff, and nosebleed questions. Troche adds mouth irritation, taste, and altered oral sensation. Exact rates are not established for these products.
Seek urgent help for chest pain, fainting, severe allergy, facial or tongue swelling, or concerning blood-pressure symptoms.
Cardiovascular and medication questions
The approved injection is contraindicated in uncontrolled hypertension and known cardiovascular disease. A needle-free route is not permission to ignore the active's cardiovascular profile.
Delayed gastric emptying can affect oral medication timing, and bremelanotide can reduce exposure to oral naltrexone. Antidepressants, antihypertensives, alcohol, and other sexual-health treatments create additional questions.
Do not combine routes or invent frequency limits. Follow the directions written for the dispensed product.
Refrigeration, privacy, and travel
Both formats are refrigerated. Keep the labeled package secure from children, pets, and accidental household use. Do not hide it in an unlabeled cosmetic container.
Nasal bottles need cap and leak protection. Troches need moisture and crush protection. Both need a travel plan that avoids freezing and direct ice-pack contact.
If a shipment arrives warm or damaged, record timing and package condition rather than deciding from touch alone.
Price, supply, and refills
Rebody's 5 mL nasal bottle is $99.50 first month, then $199. Its 8-count troche package is $54.50 first month, then $109 for 1 mg; $59.50 first month, then $119 for 2 mg. The label—not bottle volume or troche count—determines prescribed uses and refill timing.
Compare package price, expected uses, cold shipping, and the route a customer can actually complete. Do not compare cost per milligram across forms.
Checkout should show route, strength, package price, refrigeration, and prescription status without promising approval.
Questions women ask
Is there a non-injection Vyleesi?
Rebody's products contain bremelanotide but are not Vyleesi or approved as equivalent versions.
Which needle-free route is easiest?
Nasal wins for seconds-long administration. Troche wins for a compact oral-dissolve routine without a pump or liquid bottle.
What evidence makes bremelanotide compelling?
Two phase 3 injection trials found improved desire and reduced distress, while a double-blind crossover experiment directly studied intranasal bremelanotide in 18 premenopausal women. Together they support the active's desire biology and establish the nasal route as a real human research lane.
Can these products be used after menopause?
The pivotal Vyleesi population was premenopausal. Do not erase that boundary for compounded routes.
Do needle-free routes cause less nausea?
No reliable head-to-head route data establishes that. Nausea remains an important active-level concern.
Bottom line
Needle-free bremelanotide gives women two clear physical choices. Nasal spray wins for speed and a compact bottle. Mini troche wins for a private oral-dissolve routine. Both bring melanocortin-driven desire treatment into an as-needed format; choose the form that feels most realistic around intimacy.
Keep reading
- As-Needed Libido Medication Formats for Women
- Bremelanotide Options for Women With Distressing Low Desire
- PT-141 for Women: Desire, Distress, Timing, and Side Effects